<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Drugs R D</journal-id><journal-id journal-id-type="iso-abbrev">Drugs R D</journal-id><journal-title-group><journal-title>Drugs in R&#x00026;D</journal-title></journal-title-group><issn pub-type="ppub">1174-5886</issn><issn pub-type="epub">1179-6901</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26286203</article-id><article-id pub-id-type="pmc">4561049</article-id><article-id pub-id-type="publisher-id">104</article-id><article-id pub-id-type="doi">10.1007/s40268-015-0104-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research Article</subject></subj-group></article-categories><title-group><article-title>Population Pharmacokinetics and Pharmacodynamics of GSK961081 (Batefenterol), a Muscarinic Antagonist and &#x003b2;<sub>2</sub>-Agonist, in Moderate-to-Severe COPD Patients: Substudy of a Randomized Trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Ambery</surname><given-names>Claire L.</given-names></name><address><phone>+44-20-89903652</phone><email>claire.l.ambery@gsk.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Wielders</surname><given-names>Pascal</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Ludwig-Sengpiel</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Chan</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Riley</surname><given-names>John H.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><label/>GlaxoSmithKline, Stockley Park West, 1&#x02013;3 Ironbridge Road, Uxbridge, Middlesex UB11 1BT UK </aff><aff id="Aff2"><label/>Department of Pulmonary Diseases, Catharina Hospital, Michelangelolaan&#x000a0;2, 5623&#x000a0;EJ Eindhoven, The Netherlands </aff><aff id="Aff3"><label/>KLB&#x000a0;Health Research Luebeck, Pferdemarkt&#x000a0;6&#x02013;8, 23552 Luebeck, Germany </aff></contrib-group><pub-date pub-type="epub"><day>19</day><month>8</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>19</day><month>8</month><year>2015</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2015</year></pub-date><volume>15</volume><issue>3</issue><fpage>281</fpage><lpage>291</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2015</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><p>GSK961081 (batefenterol) is a novel bifunctional molecule composed
of a muscarinic antagonist and a &#x003b2;<sub>2</sub>&#x02010;agonist. The aims of this substudy were (1)&#x000a0;to characterize the population pharmacokinetics (PK) and pharmacodynamics (PD) of GSK961081 in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD); and (2)&#x000a0;to investigate the relationship between systemic exposure to GSK961081 and key cardiac-related safety parameters. Three once-daily doses (100, 400, and 800&#x000a0;&#x003bc;g) and three twice-daily doses (100, 200, and 400&#x000a0;&#x003bc;g) of GSK961081 DISKUS were investigated. A two-compartment disposition PK model with first-order absorption adequately described the plasma GSK961081 concentration&#x02013;time data. An empirical maximum-effects PD model adequately described the forced expiratory volume in 1&#x000a0;s (FEV<sub>1</sub>) response relationship with the covariate baseline FEV<sub>1</sub> on day&#x000a0;1. No clear relationships between GSK961081 plasma drug levels and cardiac-related safety parameters were apparent. The PK and PD models will be used to guide the dose selection and development of GSK961081 in patients with COPD.</p></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer International Publishing Switzerland 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="d30e229"><title>Key Points</title><p><table-wrap id="Taba"><table frame="hsides" rules="groups"><tbody><tr><td align="left">A two-compartment model accurately described the distribution of the GSK961081 concentration&#x02013;time data.</td></tr><tr><td align="left">The pharmacokinetic and pharmacodynamic models described the observed data well, with adequate goodness-of-fit diagnostic plots.</td></tr><tr><td align="left">A muscarinic antagonist and a &#x003b2;<sub>2</sub>&#x02010;agonist in one molecule may potentially lead to the development of another regimen to support the current strategy of combining &#x003b2;<sub>2</sub>&#x02010;agonists and anti&#x02010;muscarinics as inhaled bronchodilators for treatment of chronic obstructive pulmonary disease.</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec1" sec-type="intro"><title>Introduction</title><p>Chronic obstructive pulmonary disease (COPD) is a progressive disease of the respiratory system and is a major cause of morbidity and mortality worldwide [<xref ref-type="bibr" rid="CR1">1</xref>]. The primary aims of the pharmacological treatment of chronic, stable COPD are to optimize lung function, reduce exacerbations, and improve exercise tolerance and quality of life [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Current treatment strategies include the use of &#x003b2;<sub>2</sub>&#x02010;agonist (BA) therapy and anti&#x02010;muscarinic therapy delivered as inhaled bronchodilators [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p>GSK961081 (batefenterol) is a novel bifunctional molecule composed of both a muscarinic antagonist (MA) and a BA separated by an inert linker portion [<xref ref-type="bibr" rid="CR4">4</xref>]. The combination of an MA with a BA results in greater bronchodilation in the airways than either component alone [<xref ref-type="bibr" rid="CR5">5</xref>]. The bifunctional nature of GSK961081 has previously been demonstrated in&#x000a0;vitro [<xref ref-type="bibr" rid="CR6">6</xref>] and in&#x000a0;vivo [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p>A phase&#x000a0;IIb clinical trial of GSK961081 reported an improvement in the trough forced expiratory volume in 1&#x000a0;s (FEV<sub>1</sub>) of 155&#x02013;277&#x000a0;mL after 28&#x000a0;days of treatment [<xref ref-type="bibr" rid="CR8">8</xref>]. GSK961081 has a rapid onset of action and was well tolerated [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. The safety of adding short-acting bronchodilators (SABAs) to a GSK961081 treatment regimen was assessed and showed that SABAs may be used as a rescue therapy on top of muscarinic &#x003b2;<sub>2</sub>&#x02010;agonist (MABA) therapy [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p>A single compound with MABA activity, such as GSK961081, has advantages over the use of two separate compounds. As a single pharmacokinetic (PK) profile exists for both pharmacological activities, there is the potential to maximize the synergy between the two mechanisms. The technical and clinical development pathway is also simpler for a single compound than for a co&#x02010;formulation of two separate compounds [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>].</p><p>PK and pharmacodynamic (PD) modelling techniques are a recognized method used to determine the optimal dose and dose regimen of drugs under development [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. The aim of this substudy was to characterize the population PK and PD of GSK961081 in patients with moderate-to-severe COPD; the primary results from the study (GlaxoSmithKline study number MAB115032; <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</ext-link> registration number NCT01319019) have been published elsewhere [<xref ref-type="bibr" rid="CR8">8</xref>]. The resulting data will be used to help define the most appropriate dose and dose interval in future clinical trials of GSK961081. Long-acting &#x003b2;<sub>2</sub>-agonists have been associated with cardiac-related effects, showing potential to increase the heart rate and cause corrected QT&#x000a0;interval (QTc) prolongation and ventricular arrhythmias in patients with COPD [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Therefore, we also investigated the relationship between systemic exposure to GSK961081 (containing a &#x003b2;<sub>2</sub>-agonist) and key cardiac-related safety parameters.</p></sec><sec id="Sec2" sec-type="methods"><title>Methods</title><sec id="Sec3"><title>Study Design</title><p>This PK and PD assessment of GSK961081 was part of a 4&#x02010;week, multicenter, randomized, double-blind, double-dummy, placebo- and salmeterol-controlled parallel-group study, which has been published elsewhere [<xref ref-type="bibr" rid="CR8">8</xref>] (GlaxoSmithKline study number MAB115032; <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</ext-link> registration number NCT01319019). In this substudy, we report the PK and PD analyses of the active treatment, GSK961081. Three once-daily doses (100, 400, and 800&#x000a0;&#x003bc;g) administered in the morning and three twice-daily doses (100, 200, and 400&#x000a0;&#x003bc;g) of GSK961081 DISKUS were investigated.</p></sec><sec id="Sec4"><title>Study Patients</title><p>Male and female outpatients aged &#x02265;40&#x000a0;years who were either current or former smokers with a smoking history of &#x02265;10 pack&#x02010;years were recruited. The patients had a clinical diagnosis of moderate&#x02010;to&#x02010;severe stable COPD, based on spirometric normative values according to the National Health and Nutritional Examination Survey&#x000a0;III [<xref ref-type="bibr" rid="CR17">17</xref>] (post-bronchodilator FEV<sub>1</sub>/forced vital capacity &#x0003c;70 and FEV<sub>1</sub> &#x02265;30 and &#x02264;70&#x000a0;% predicted). Patients receiving a stable dose of inhaled corticosteroids were eligible for enrollment. Patients diagnosed with asthma were excluded.</p><p>The study was approved by the medical ethics committees at the participating centers, and all participants gave their written informed consent for participation. The study was conducted according to the Declaration of Helsinki [<xref ref-type="bibr" rid="CR18">18</xref>] and Good Clinical Practice guidelines [<xref ref-type="bibr" rid="CR19">19</xref>]. The characteristics of the study population are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Demographic characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristic</th><th align="left">PD and PK/PD</th><th align="left">PK model-building</th></tr></thead><tbody><tr><td align="left">
<italic>n</italic>
</td><td align="left">347</td><td align="left">47</td></tr><tr><td align="left">Age (years)<sup>a</sup>
</td><td align="left">63&#x000a0;&#x000b1;&#x000a0;8.2</td><td align="left">63&#x000a0;&#x000b1;&#x000a0;8.9</td></tr><tr><td align="left">Weight (kg)<sup>a</sup>
</td><td align="left">76&#x000a0;&#x000b1;&#x000a0;14</td><td align="left">72&#x000a0;&#x000b1;&#x000a0;13</td></tr><tr><td align="left">Height (cm)<sup>a</sup>
</td><td align="left">171&#x000a0;&#x000b1;&#x000a0;8.5</td><td align="left">169&#x000a0;&#x000b1;&#x000a0;7.7</td></tr><tr><td align="left">Male (%)</td><td align="left">65</td><td align="left">62</td></tr><tr><td align="left">Current smoker (%)</td><td align="left">49</td><td align="left">49</td></tr><tr><td align="left">Concurrent ICS use (%)</td><td align="left">58</td><td align="left">53</td></tr><tr><td align="left">Baseline FEV<sub>1</sub> on day&#x000a0;1 (L)<sup>a</sup>
</td><td align="left">1.31&#x000a0;&#x000b1;&#x000a0;0.46</td><td align="left">1.36&#x000a0;&#x000b1;&#x000a0;0.42</td></tr></tbody></table><table-wrap-foot><p>
<italic>FEV</italic>
<sub><italic>1</italic></sub>&#x000a0;forced expiratory volume in 1&#x000a0;s, <italic>ICS</italic>&#x000a0;inhaled corticosteroid, <italic>PD</italic>&#x000a0;pharmacodynamics, <italic>PK</italic>&#x000a0;pharmacokinetic(s)</p><p>
<sup>a</sup>The data are presented as means&#x000a0;&#x000b1;&#x000a0;standard deviations</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec5"><title>Study Assessments</title><p>Spirometry FEV<sub>1</sub> was performed in all patients, using a Vitalograph (Biomedical Systems, Brussels, Belgium). The day&#x000a0;29 trough FEV<sub>1</sub> was defined as the mean of the 11 and 12&#x000a0;h measurements after the evening dosing on day&#x000a0;28.</p><p>PK blood sampling was performed in a subset of patients at overnight sites. On day&#x000a0;28, following administration of both the morning and the evening doses, blood samples were collected at 1&#x000a0;h to 0&#x000a0;min before dosing and then at 0&#x02013;30&#x000a0;min, 30&#x000a0;min&#x02013;2 h, 2&#x02013;6&#x000a0;h, and 6&#x02013;11&#x000a0;h after dosing.</p><p>PK analysis of GSK961081 concentrations was performed using a validated high-performance liquid chromatography and mass spectrometry method with a lower limit of quantification (LLOQ) of 25&#x000a0;pg/mL. The detailed bioanalytical methodology has been reported previously [<xref ref-type="bibr" rid="CR4">4</xref>]. PK samples obtained from patients in the placebo and salmeterol treatment groups were not analyzed.</p></sec><sec id="Sec6"><title>Pharmacokinetic and Pharmacodynamic Analyses</title><p>Plasma concentrations of GSK961081, expressed as natural logarithms and trough FEV<sub>1</sub> values, were modelled using NONMEM version&#x000a0;7 software (ICON Developments Solutions, Dublin, Ireland). The first-order conditional estimation method with interaction was used for the PD model, and all data were used in the model-building. The Monte Carlo importance sampling method was used for the PK model. The M3 methodology was used to maximize the likelihood for the plasma GSK961081 data, treating those data that were below the LLOQ as censored for the PK model [<xref ref-type="bibr" rid="CR20">20</xref>]. The percentage of PK data below the LLOQ was &#x0003e;50&#x000a0;% for all GSK961081 treatments, except for 800&#x000a0;&#x003bc;g once daily on days 1 and 28, and 400&#x000a0;&#x003bc;g twice daily on day&#x000a0;28. Therefore, the PK model-building data set comprised data from the 800&#x000a0;&#x003bc;g once-daily and 400 &#x003bc;g twice-daily treatment groups on day&#x000a0;28 only, of which 30 and 27&#x000a0;% of the data, respectively, were below the LLOQ. The full PK data set comprised data from all GSK961081 treatment groups.</p><p>Model selection was based on the objective function values computed by NONMEM, goodness-of-fit graphical checking, and physiological plausibility of parameters. Potential covariates were investigated using a stepwise forward addition and backward elimination approach for the PD model only [<xref ref-type="bibr" rid="CR21">21</xref>]. The covariates baseline FEV<sub>1</sub> on day&#x000a0;1, age, weight, sex, height, smoking status, and inhaled corticosteroid use were investigated. A <italic>p</italic>&#x000a0;value of &#x0003c;0.01 was used in the forward step and a <italic>p</italic>&#x000a0;value of &#x0003c;0.001 was used in the backward step. Simulation-based diagnostics and re-estimation methods were used to evaluate the performance of the PK and PD final models [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p>Relationships between selected PD endpoints [including the glucose level, heart rate, QT interval corrected for the heart rate using Fridericia&#x02019;s correction (QTcF), and potassium level] and systemic exposure to GSK961081 [the maximum plasma drug concentration (<italic>C</italic><sub>max</sub>)] were explored graphically. Placebo data were plotted using a value of 0&#x000a0;pg/mL, and GSK961081 values below the LLOQ were plotted as 12.5&#x000a0;pg/mL (i.e.,&#x000a0;half the LLOQ of the GSK961081 assay).</p></sec></sec><sec id="Sec7" sec-type="results"><title>Results</title><sec id="Sec8"><title>Pharmacokinetics</title><p>A total of 405 GSK961081 PK samples from 47 patients were included in the model-building PK data set. This comprised data from the 800&#x000a0;&#x003bc;g once-daily and 400&#x000a0;&#x003bc;g twice-daily treatment groups only (see Sect. <xref rid="Sec2" ref-type="sec">2</xref>). A two-compartment disposition model (ADVAN4 TRANS4) with first-order absorption was adequate to describe the plasma GSK961081 concentration&#x02013;time data (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Interindividual variability could be estimated reliably for the apparent elimination clearance. Covariates were not included in the PK model, because of the limited data set.<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Pharmacokinetic (PK) model parameters</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">PK parameter</th><th align="left">Log estimate</th><th align="left">RSE (%)</th><th align="left">95&#x000a0;%&#x000a0;CI</th></tr></thead><tbody><tr><td align="left">CL/<italic>F</italic> (L/h)</td><td char="." align="char">6.85</td><td char="." align="char">1.72</td><td char="t" align="char">6.62 to 7.08</td></tr><tr><td align="left">
<italic>V</italic>
<sub>2</sub>/<italic>F</italic> (L)</td><td char="." align="char">6.26</td><td char="." align="char">3.71</td><td char="t" align="char">5.82 to 6.72</td></tr><tr><td align="left">KA (h<sup>&#x02212;1</sup>)</td><td char="." align="char">&#x02212;0.89</td><td char="." align="char">&#x02212;15.2</td><td char="t" align="char">&#x02212;1.16 to &#x02212;0.625</td></tr><tr><td align="left">
<italic>V</italic>
<sub>3</sub>/<italic>F</italic> (L)</td><td char="." align="char">9.97</td><td char="." align="char">2.90</td><td char="t" align="char">9.40 to 10.5</td></tr><tr><td align="left">
<italic>Q</italic> (L/h)</td><td char="." align="char">7.25</td><td char="." align="char">2.17</td><td char="t" align="char">6.94 to 7.56</td></tr><tr><td align="left">Interindividual variability CL/<italic>F</italic>
</td><td char="." align="char">0.594</td><td char="." align="char">0.137</td><td char="t" align="char">0.325 to 0.863</td></tr><tr><td align="left">Proportional residual error</td><td char="." align="char">0.365</td><td char="." align="char">0.0175</td><td char="t" align="char">0.331 to 0.399</td></tr></tbody></table><table-wrap-foot><p>
<italic>CI</italic>&#x000a0;confidence interval, <italic>CL/F</italic>&#x000a0;apparent clearance, <italic>KA</italic>&#x000a0;absorption rate constant, <italic>Q</italic>&#x000a0;intercompartmental clearance, <italic>RSE</italic>&#x000a0;relative standard error, <italic>V</italic>
<sub><italic>2</italic></sub>
<italic>/F</italic>&#x000a0;apparent central volume of distribution, <italic>V</italic>
<sub><italic>3</italic></sub>
<italic>/F</italic>&#x000a0;apparent peripheral volume of distribution</p></table-wrap-foot></table-wrap></p><p>The PK model described the observed data well, with adequate goodness-of-fit diagnostic plots (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). A visual predictive check of the model showed no model misspecifications and good simulation properties for both the model-building data set and the full data set (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). The full data set comprised 1112 GSK961081 PK samples from 128 patients (see Sect. <xref rid="Sec2" ref-type="sec">2</xref>). Bootstrapping confirmed the reliability of the PK model parameter estimates (data not shown).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Goodness-of-fit of the final pharmacokinetic model.<bold> a</bold>&#x000a0;Logarithmic plasma GSK961081 concentrations on day&#x000a0;28 versus population predictions.<bold> b</bold>&#x000a0;Logarithmic plasma GSK961081 concentrations on day&#x000a0;28 versus individual predictions.<bold> c</bold>&#x000a0;Conditional weighted residuals versus population predictions.<bold> d</bold>&#x000a0;Conditional weighted residuals versus time. The <italic>solid lines</italic> indicate the identity lines, and the <italic>dashed lines</italic> indicate the loess smooths</p></caption><graphic xlink:href="40268_2015_104_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Visual predictive check of the final pharmacokinetic model, showing the logarithmic plasma GSK961081 concentrations versus time on day&#x000a0;28 for<bold> a</bold>&#x000a0;100&#x000a0;&#x003bc;g twice daily,<bold> b</bold>&#x000a0;200&#x000a0;&#x003bc;g twice daily,<bold> c</bold>&#x000a0;400&#x000a0;&#x003bc;g twice daily,<bold> d</bold>&#x000a0;100&#x000a0;&#x003bc;g once daily,<bold> e</bold>&#x000a0;400&#x000a0;&#x003bc;g once daily, and<bold> f</bold>&#x000a0;800&#x000a0;&#x003bc;g once daily. The <italic>horizontal lines</italic> indicate the lower limits of quantification for the pharmacokinetic assay, the <italic>solid lines</italic> indicate the population means, the <italic>dashed lines</italic> indicate the 95&#x000a0;% prediction intervals, the <italic>dotted lines</italic> indicate the observed means, and the <italic>dashed-dotted lines</italic> indicate the upper limits of the observed 95&#x000a0;% prediction intervals. <italic>Shaded areas</italic> indicate the 95&#x000a0;% confidence interval of the prediction interval. <italic>TRT</italic> treatment</p></caption><graphic xlink:href="40268_2015_104_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec9"><title>Pharmacodynamics</title><p>A total of 347 trough FEV<sub>1</sub> samples from 347 patients were included in the PD data set. A summary of patient demographics and clinical characteristics at screening was published in the primary paper (see the GSK961081 and placebo treatment groups only) [<xref ref-type="bibr" rid="CR8">8</xref>]. An empirical maximum-effects (<italic>E</italic><sub>max</sub>) model (Eq.&#x000a0;<xref rid="Equ1" ref-type="">1</xref>) was adequate to describe the FEV<sub>1</sub> response relationship (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>), with the baseline FEV<sub>1</sub> on day&#x000a0;1 as a covariate (Eq. <xref rid="Equ2" ref-type="">2</xref>):<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ {\text{Effect}} = (E_{0} \times {\text{COV}}) + E_{\hbox{max} } \frac{\text{Total Dose}}{{{\text{Total Dose}} + {\text{ED}}_{50} }} $$\end{document}</tex-math><mml:math id="M2" display="block"><mml:mrow><mml:mtext>Effect</mml:mtext><mml:mo>=</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>E</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>&#x000d7;</mml:mo><mml:mtext>COV</mml:mtext><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>E</mml:mi><mml:mtext>max</mml:mtext></mml:msub><mml:mfrac><mml:mrow><mml:mtext>Total Dose</mml:mtext></mml:mrow><mml:mrow><mml:mrow><mml:mtext>Total Dose</mml:mtext></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mtext>ED</mml:mtext><mml:mn>50</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:math><graphic xlink:href="40268_2015_104_Article_Equ1.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equ2"><label>2</label><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ {\text{COV}} = {\text{CON}} \times \frac{{{\text{Baseline FEV}}_{1} {\text{ on Day }}1}}{{{\text{Median Baseline FEV}}_{1} {\text{ on Day }}1}} $$\end{document}</tex-math><mml:math id="M4" display="block"><mml:mrow><mml:mtext>COV</mml:mtext><mml:mo>=</mml:mo><mml:mtext>CON</mml:mtext><mml:mo>&#x000d7;</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mtext>Baseline FEV</mml:mtext></mml:mrow><mml:mn>1</mml:mn></mml:msub><mml:mrow><mml:mspace width="0.333333em"/><mml:mtext>on Day</mml:mtext><mml:mspace width="0.333333em"/></mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mtext>Median Baseline FEV</mml:mtext></mml:mrow><mml:mn>1</mml:mn></mml:msub><mml:mrow><mml:mspace width="0.333333em"/><mml:mtext>on Day</mml:mtext><mml:mspace width="0.333333em"/></mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:math><graphic xlink:href="40268_2015_104_Article_Equ2.gif" position="anchor"/></alternatives></disp-formula>where <italic>E</italic><sub>max</sub> is the trough FEV<sub>1</sub> at the maximum effect, <italic>E</italic><sub>0</sub> is the FEV<sub>1</sub> at zero dose, ED<sub>50</sub> is the dose producing 50&#x000a0;% of the maximum effect, and CON is the baseline FEV<sub>1</sub> covariate effect.<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Pharmacodynamic (PD) model parameters</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">PD parameter</th><th align="left">Estimate</th><th align="left">RSE (%)</th><th align="left">95&#x000a0;%&#x000a0;CI</th></tr></thead><tbody><tr><td align="left">
<italic>E</italic>
<sub>max</sub> (L)</td><td align="left">0.293</td><td char="." align="char">14.9</td><td char="&#x02013;" align="char">0.207&#x02013;0.379</td></tr><tr><td align="left">ED<sub>50</sub> (&#x000b5;g)</td><td align="left">152</td><td char="." align="char">50.2</td><td char="&#x02013;" align="char">2.45&#x02013;302</td></tr><tr><td align="left">Intercept for <italic>E</italic>
<sub>0</sub> (L)</td><td align="left">0.0650</td><td char="." align="char">32.8</td><td char="&#x02013;" align="char">0.0233&#x02013;0.107</td></tr><tr><td align="left">Baseline (L)</td><td align="left">19.0</td><td char="." align="char">36.9</td><td char="&#x02013;" align="char">5.24&#x02013;32.8</td></tr><tr><td align="left">Proportional residual error</td><td align="left">0.204</td><td char="." align="char">30.8</td><td char="&#x02013;" align="char">0.0809&#x02013;0.327</td></tr></tbody></table><table-wrap-foot><p>
<italic>CI</italic>&#x000a0;confidence interval, <italic>E</italic>
<sub><italic>0</italic></sub>&#x000a0;FEV<sub>1</sub> at zero dose, <italic>ED</italic>
<sub><italic>50</italic></sub>&#x000a0;dose producing 50&#x000a0;% of the maximum effect, <italic>E</italic>
<sub><italic>max</italic></sub>&#x000a0;trough FEV<sub>1</sub> at the maximum effect, <italic>RSE</italic>&#x000a0;relative standard error</p></table-wrap-foot></table-wrap></p><p>The PD model described the observed data well, with adequate goodness-of-fit diagnostic plots (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). A visual predictive check of the model showed no model misspecifications, good simulation properties (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>), and good agreement with the primary endpoint analysis [<xref ref-type="bibr" rid="CR8">8</xref>]. Bootstrapping confirmed the reliability of the PD model parameter estimates (data not shown).<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Goodness-of-fit of the final pharmacodynamic model.<bold> a</bold>&#x000a0;Trough forced expiratory volume in 1&#x000a0;s (FEV<sub>1</sub>) values on day&#x000a0;29 versus population predictions.<bold> b</bold>&#x000a0;Trough FEV<sub>1</sub> values on day&#x000a0;29 versus individual predictions.<bold> c</bold>&#x000a0;Conditional weighted residuals versus population predictions.<bold> d</bold>&#x000a0;Conditional weighted residuals versus total daily doses. The <italic>solid lines</italic> indicate the identity lines, and the <italic>dashed lines</italic> indicate the loess smooths</p></caption><graphic xlink:href="40268_2015_104_Fig3_HTML" id="MO5"/></fig><fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Visual predictive check of the final pharmacodynamic model. a&#x000a0;Day&#x000a0;29 trough forced expiratory volume in 1&#x000a0;s (FEV<sub>1</sub>) values versus total daily doses; the <italic>white circles</italic> indicate observed data, the <italic>solid line</italic> indicates the population means, and the <italic>dashed lines</italic> indicate the 95&#x000a0;% prediction intervals.<bold> b</bold>&#x000a0;Day&#x000a0;29 placebo-corrected changes from baseline trough FEV<sub>1</sub> values versus total daily doses; the <italic>black circles</italic> indicate once-daily dosing, the <italic>black triangles</italic> indicate the twice-daily dosing least squares means (with 95&#x000a0;% confidence intervals) from Wielders et al., the <italic>solid line</italic> indicates the pharmacodynamic model population medians, and the <italic>dashed lines</italic> indicate the pharmacodynamic model 95&#x000a0;% prediction intervals</p></caption><graphic xlink:href="40268_2015_104_Fig4_HTML" id="MO6"/></fig></p></sec><sec id="Sec10"><title>Relationship Between Exposure and Safety Endpoints</title><p>The PK/PD analyses evaluated the relationship between key safety endpoints and systemic exposure to GSK961081. No clear relationships between maximum glucose, heart rate, QTcF and minimum potassium versus individual observed GSK961081 plasma drug levels (<italic>C</italic><sub>max</sub>) were apparent (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). It should be noted that these analyses were limited by high variability in the placebo response and a large number of patients with a <italic>C</italic><sub>max</sub> below the LLOQ. Exploratory PK/PD analysis by way of generalized linear models did not show any significant relationships (data not shown). Similar evaluation of weighted mean changes in glucose levels, heart rate, QTcF, and potassium levels (0&#x02013;4&#x000a0;h) from baseline versus individual observed GSK961081 <italic>C</italic><sub>max</sub> values also showed no clear relationships with safety endpoints (data not shown).<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Scatter plots of observed maximum plasma GSK961081 concentration (<italic>C</italic>
<sub>max</sub>) values versus pharmacodynamic endpoints (regression plots) from 0 to 4&#x000a0;h on day&#x000a0;1 (<italic>left-hand panels</italic>) and day&#x000a0;28 (<italic>right-hand panels</italic>) for<bold> a</bold>&#x000a0;maximum glucose level,<bold> b</bold>&#x000a0;maximum heart rate,<bold> c</bold>&#x000a0;maximum QT interval corrected for the heart rate using Fridericia&#x02019;s correction (QTcF), and<bold> d</bold>&#x000a0;maximum potassium level. The <italic>white circles</italic> indicate once-daily dosing, and the <italic>crosses</italic> indicate twice-daily dosing. For <italic>C</italic>
<sub>max</sub>, placebo&#x000a0;=&#x000a0;0&#x000a0;pg/mL, NQ&#x000a0;=&#x000a0;LLOQ/2, LLOQ&#x000a0;=&#x000a0;25&#x000a0;pg/mL (indicated by the <italic>dashed vertical lines</italic>). <italic>bpm</italic>&#x000a0;beats per minute, <italic>LLOQ</italic>&#x000a0;lower limit of quantification, <italic>NQ</italic>&#x000a0;not quantifiable</p></caption><graphic xlink:href="40268_2015_104_Fig5_HTML" id="MO7"/></fig></p></sec></sec><sec id="Sec11" sec-type="discussion"><title>Discussion</title><p>This substudy is the first to report the population PK and PD of GSK961081 in patients with moderate-to-severe COPD. This information is important in the guidance of dose selection and subsequent clinical development of this novel compound. A two-compartment model accurately described the distribution of the GSK961081 concentration&#x02013;time data. This substudy had a small number of patients because of limited PK sampling and a large number of non-quantifiable data. Due to the limited data available, covariates were not included in the PK model. We followed the recommendations of Ribbing and Jonsson [<xref ref-type="bibr" rid="CR22">22</xref>], who suggested that stepwise selection of covariates or significance testing of covariates should not be used in data sets of less than 50&#x02013;100 subjects.</p><p>An <italic>E</italic><sub>max</sub> model described the trough FEV<sub>1</sub> response on day&#x000a0;29. The primary study showed that there was only a small increase in the trough FEV<sub>1</sub> from 400 to 800&#x000a0;&#x003bc;g, and concluded that a total daily dose of 400&#x000a0;&#x003bc;g may be the optimal dose [<xref ref-type="bibr" rid="CR8">8</xref>]. These results are consistent with the final PD model reported here. As PK/PD models are an important tool in drug development [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>], our PK/PD modelling results with GSK961081 will aid dose selection for further studies of this novel compound in patients with COPD.</p><p>There were some limitations to this substudy. The number of different treatment doses investigated was small, and once-daily and twice-daily doses were combined for the PD analysis. However, there was no apparent influence of dosing regimen on the PD model, indicating that there was no apparent difference between once-daily and twice-daily dosing for the primary endpoint of the day&#x000a0;29 trough FEV<sub>1</sub>&#x02014;a finding also reported in the primary publication [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p>Long-acting &#x003b2;<sub>2</sub>-agonists have been associated with cardiac-related effects [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Over the doses of GSK961081 assessed in the current study, PK/PD analyses revealed no apparent relationship between individual <italic>C</italic><sub>max</sub> values and any increase in the heart rate or QTcF. Furthermore, no clear relationship with blood potassium or glucose values was observed. The range of <italic>C</italic><sub>max</sub> values in this substudy was limited, and we were not able to quantify this parameter in all patients. However, these results support the safety findings reported in the primary publication [<xref ref-type="bibr" rid="CR8">8</xref>] that GSK961081 has no effect on glucose levels, potassium levels, heart rate, or blood pressure. In addition, although GSK961081 was associated with prolongation of various QTc intervals (by 3&#x02013;5&#x000a0;ms, in comparison with placebo or salmeterol), there was no apparent dose response [<xref ref-type="bibr" rid="CR8">8</xref>]. A previous study that investigated GSK961081 at a dose of 1200&#x000a0;&#x000b5;g once daily demonstrated that there was no prolongation of the QT interval [<xref ref-type="bibr" rid="CR23">23</xref>]. Collectively, these data suggest that at the wide range of doses evaluated to date, GSK961081 may not be expected to induce cardiac-related effects; however, the current data are preliminary, and longer-term studies are required in patients with COPD to fully evaluate the tolerability profile of this compound.</p><p>COPD treatment guidelines recommend the use of combination bronchodilator therapy if patients remain symptomatic on a single bronchodilator [<xref ref-type="bibr" rid="CR2">2</xref>]. Preclinical investigation of the effect of delivering two bronchodilators with different mechanisms of action has demonstrated a significant synergistic interaction in the bronchorelaxant response of human airways [<xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>]. As a bifunctional molecule composed of both an MA and a BA, GSK961081 is postulated to have an advantage over combinations using two separate compounds, as the pharmacological activities are from a single molecule, thus ensuring co-localization at the site of action, potentially increasing the degree of bronchodilation with similar side effects.</p></sec><sec id="Sec12" sec-type="conclusions"><title>Conclusion</title><p>The PK and PD models described in this substudy will be used as tools to guide the dose selection and clinical development of GSK961081 in patients with COPD. This novel compound combines two active moieties&#x02014;an MA and a BA&#x02014;in one molecule and may potentially lead to the development of another regimen to support the current strategy of combining &#x003b2;<sub>2</sub>&#x02010;agonists and anti&#x02010;muscarinics as inhaled bronchodilators for COPD treatment [<xref ref-type="bibr" rid="CR2">2</xref>]. A further potential role of an MABA molecule may be as part of a triple COPD therapy delivered via a single inhaler [<xref ref-type="bibr" rid="CR10">10</xref>].</p></sec></body><back><ack><p>We wish to acknowledge the investigators, staff, and patients at the study sites, without whom this research could not have been conducted. Editorial support (in the form of development of the manuscript first draft, in consultation with the authors) was provided by Ian Grieve, PhD, at Gardiner&#x02010;Caldwell Communications (Macclesfield, Cheshire, UK). Editorial support in the form of editorial suggestions on draft versions of this paper, assembling tables, collating author comments, copyediting, fact checking, and referencing were provided by Jackie Phillipson, PhD, at Gardiner-Caldwell Communications (Macclesfield, Cheshire, UK). Editorial support in the form of collation of author comments, redrawing of figures, and resubmission was provided by Joanne Ashworth of Fishawack Indicia Ltd. All editorial support was funded by GlaxoSmithKline.</p></ack><notes notes-type="conflict-interest"><title>Compliance with Ethical Standards</title><sec id="d30e1447"><title>Statement of interest</title><p>CLA, RC, and JHR are employees of, and hold stock in, GlaxoSmithKline. PW has received reimbursement for attendance at symposia and speaker&#x02019;s fees from AstraZeneca, Boehringer Ingelheim, Chiesi Pharmaceuticals, GlaxoSmithKline, and Novartis Pharma. PW&#x02019;s research institute has received grants from AstraZeneca and GlaxoSmithKline. ALS reports no conflict of interests.</p></sec><sec id="d30e1452"><title>Ethical standards</title><p>This study was approved by the medical ethics committees at the participating centers, and all participants gave their written informed consent for participation. The study was conducted according to the Declaration of Helsinki [<xref ref-type="bibr" rid="CR18">18</xref>] and Good Clinical Practice guidelines [<xref ref-type="bibr" rid="CR19">19</xref>].</p></sec><sec id="d30e1463"><title>Support statement</title><p>This study was funded by GlaxoSmithKline.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">World Health Organization. Health topics: chronic obstructive pulmonary disease. 2015. <ext-link ext-link-type="uri" xlink:href="http://www.who.int/topics/chronic_obstructive_pulmonary_disease/en/">http://www.who.int/topics/chronic_obstructive_pulmonary_disease/en/</ext-link>. Accessed 19 Feb 2015.</mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of COPD. 2015. <ext-link ext-link-type="uri" xlink:href="http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html">http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html</ext-link>. Accessed 19 Feb 2015.</mixed-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Celli</surname><given-names>BR</given-names></name><name><surname>MacNee</surname><given-names>W</given-names></name></person-group><article-title>Standards of the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper</article-title><source>Eur Respir J.</source><year>2004</year><volume>23</volume><fpage>932</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1183/09031936.04.00014304</pub-id><pub-id pub-id-type="pmid">15219010</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norris</surname><given-names>V</given-names></name><name><surname>Ambery</surname><given-names>C</given-names></name><name><surname>Riley</surname><given-names>T</given-names></name></person-group><article-title>Pharmacokinetics and pharmacodynamics of GSK961081, a novel inhaled muscarinic antagonist b2-agonist, and fluticasone propionate administered alone, concurrently and as a combination blend formulation in healthy volunteers</article-title><source>Clin Pharmacol Drug Dev.</source><year>2014</year><volume>3</volume><fpage>305</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1002/cpdd.105</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cazzola</surname><given-names>M</given-names></name><name><surname>Molimard</surname><given-names>M</given-names></name></person-group><article-title>The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD</article-title><source>Pulm Pharmacol Ther.</source><year>2010</year><volume>23</volume><fpage>257</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1016/j.pupt.2010.03.003</pub-id><pub-id pub-id-type="pmid">20381630</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aiyar</surname><given-names>J</given-names></name><name><surname>Steinfeld</surname><given-names>T</given-names></name><name><surname>Pulido-Rios</surname><given-names>MT</given-names></name><name><surname>Chin</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>TW</given-names></name><name><surname>Jasper</surname><given-names>J</given-names></name><name><surname>Thomas</surname><given-names>R</given-names></name><name><surname>Hegde</surname><given-names>S</given-names></name><name><surname>Mammen</surname><given-names>M</given-names></name></person-group><article-title>In&#x000a0;vitro characterization of TD&#x02212;5959: a novel bifunctional molecule with muscarinic antagonist and &#x003b2;<sub>2</sub>&#x02212;adrenergic agonist activity</article-title><source>Am J Respir Crit Care Med.</source><year>2009</year><volume>179</volume><fpage>A4552</fpage></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pulido-Rios</surname><given-names>MT</given-names></name><name><surname>McNamara</surname><given-names>A</given-names></name><name><surname>Kwan</surname><given-names>K</given-names></name><name><surname>Martin</surname><given-names>W</given-names></name><name><surname>Thomas</surname><given-names>R</given-names></name><name><surname>Mammen</surname><given-names>M</given-names></name><name><surname>Hegde</surname><given-names>S</given-names></name></person-group><article-title>TD&#x02212;5959: a novel bifunctional muscarinic antagonist&#x02212;&#x003b2;<sub>2</sub>-adrenergic agonist with potent and sustained in&#x000a0;vivo bronchodilator activity in guinea pigs</article-title><source>Am J Respir Crit Care Med.</source><year>2009</year><volume>179</volume><fpage>A6195</fpage></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wielders</surname><given-names>PL</given-names></name><name><surname>Ludwig-Sengpiel</surname><given-names>A</given-names></name><name><surname>Locantore</surname><given-names>N</given-names></name><name><surname>Baggen</surname><given-names>S</given-names></name><name><surname>Chan</surname><given-names>R</given-names></name><name><surname>Riley</surname><given-names>JH</given-names></name></person-group><article-title>A new class of bronchodilator improves lung function in COPD: a trial with GSK961081</article-title><source>Eur Respir J.</source><year>2013</year><volume>42</volume><fpage>972</fpage><lpage>981</lpage><pub-id pub-id-type="doi">10.1183/09031936.00165712</pub-id><pub-id pub-id-type="pmid">23429913</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bateman</surname><given-names>ED</given-names></name><name><surname>Kornmann</surname><given-names>O</given-names></name><name><surname>Ambery</surname><given-names>C</given-names></name><name><surname>Norris</surname><given-names>V</given-names></name></person-group><article-title>Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD</article-title><source>Pulm Pharm Ther.</source><year>2013</year><volume>26</volume><fpage>581</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1016/j.pupt.2013.03.015</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norris</surname><given-names>V</given-names></name><name><surname>Ambery</surname><given-names>C</given-names></name></person-group><article-title>Bronchodilation and safety of supratherapeutic doses of salbutamol or ipratropium bromide added to single dose GSK961081 in patients with moderate to severe COPD</article-title><source>Pulm Pharm Ther.</source><year>2013</year><volume>26</volume><fpage>574</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1016/j.pupt.2013.03.009</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Jacobsen</surname><given-names>JR</given-names></name><name><surname>Aiyar</surname><given-names>J</given-names></name><name><surname>Hegde</surname><given-names>S</given-names></name><name><surname>Hughes</surname><given-names>AD</given-names></name><name><surname>Mammen</surname><given-names>M</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Hansel</surname><given-names>TT</given-names></name><name><surname>Barnes</surname><given-names>PJ</given-names></name></person-group><article-title>Dual&#x02010;pharmacology bronchodilators for the treatment of COPD</article-title><source>New drugs and targets for asthma and COPD. Progressive respiratory research</source><year>2000</year><publisher-loc>Basel</publisher-loc><publisher-name>Karger</publisher-name><fpage>39</fpage><lpage>45</lpage></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cazzola</surname><given-names>M</given-names></name><name><surname>Lopez-Campos</surname><given-names>JL</given-names></name><name><surname>Puente-Maestu</surname><given-names>L</given-names></name></person-group><article-title>The MABA approach: a new option to improve bronchodilator therapy</article-title><source>Eur Respir J.</source><year>2013</year><volume>42</volume><fpage>885</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.1183/09031936.00067013</pub-id><pub-id pub-id-type="pmid">24081753</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibbs</surname><given-names>JP</given-names></name></person-group><article-title>Prediction of exposure&#x02013;response relationships to support first-in-human study design</article-title><source>AAPS J.</source><year>2010</year><volume>12</volume><fpage>750</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1208/s12248-010-9236-7</pub-id><pub-id pub-id-type="pmid">20967521</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000e4;ckman</surname><given-names>P</given-names></name><name><surname>Adelmann</surname><given-names>H</given-names></name><name><surname>Petersson</surname><given-names>G</given-names></name><name><surname>Jones</surname><given-names>CB</given-names></name></person-group><article-title>Advances in inhaled technologies: understanding the therapeutic challenge, predicting clinical performance, and designing the optimal inhaled product</article-title><source>Clin Pharmacol Ther.</source><year>2014</year><volume>95</volume><fpage>509</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1038/clpt.2014.27</pub-id><pub-id pub-id-type="pmid">24503626</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salpeter</surname><given-names>SR</given-names></name><name><surname>Ormiston</surname><given-names>TM</given-names></name><name><surname>Salpeter</surname><given-names>EE</given-names></name></person-group><article-title>Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis</article-title><source>Chest</source><year>2004</year><volume>125</volume><fpage>2309</fpage><lpage>2321</lpage><pub-id pub-id-type="doi">10.1378/chest.125.6.2309</pub-id><pub-id pub-id-type="pmid">15189956</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milic</surname><given-names>M</given-names></name><name><surname>Bao</surname><given-names>X</given-names></name><name><surname>Rizos</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Ziegler</surname><given-names>MG</given-names></name></person-group><article-title>Literature review and pilot studies of the effect of QT correction formulas on reported beta2-agonist-induced QTc prolongation</article-title><source>Clin Ther.</source><year>2006</year><volume>28</volume><fpage>582</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2006.04.010</pub-id><pub-id pub-id-type="pmid">16750469</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hankinson</surname><given-names>JL</given-names></name><name><surname>Odencrantz</surname><given-names>JR</given-names></name><name><surname>Fedan</surname><given-names>KB</given-names></name></person-group><article-title>Spirometric reference values from a sample of the general US population</article-title><source>Am J Respir Crit Care Med.</source><year>1999</year><volume>159</volume><fpage>179</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.159.1.9712108</pub-id><pub-id pub-id-type="pmid">9872837</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">World Medical Association. World Medical Association Declaration of Helsinki&#x02014;ethical principles for medical research involving human subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and amended [most recently] by the 64th WMA General Assembly, Fortaleza, Brazil, October 2013. 2015. <ext-link ext-link-type="uri" xlink:href="http://www.wma.net/en/30publications/10policies/b3/index.html">http://www.wma.net/en/30publications/10policies/b3/index.html</ext-link>. Accessed 19 Feb 2015.</mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline: guidance for good clinical practice E6 (R1). 1996. <ext-link ext-link-type="uri" xlink:href="http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf">http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf</ext-link>. Accessed 19 Feb 2015.</mixed-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>EA</given-names></name><name><surname>Karlsson</surname><given-names>MO</given-names></name><name><surname>Dunne</surname><given-names>A</given-names></name><name><surname>Ludden</surname><given-names>TM</given-names></name></person-group><article-title>Likelihood based approaches to handling data below the quantification limit using NONMEM&#x000a0;VI</article-title><source>J Pharmacokinet Pharmacodyn.</source><year>2008</year><volume>35</volume><fpage>401</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1007/s10928-008-9094-4</pub-id><pub-id pub-id-type="pmid">18686017</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandema</surname><given-names>JW</given-names></name><name><surname>Verotta</surname><given-names>JW</given-names></name><name><surname>Sheiner</surname><given-names>LB</given-names></name></person-group><article-title>Building population pharmacokinetic&#x02013;pharmacodynamic models. I.&#x000a0;Models for covariate effects</article-title><source>J Pharmacokinet Biopharm.</source><year>1992</year><volume>20</volume><fpage>511</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1007/BF01061469</pub-id><pub-id pub-id-type="pmid">1287200</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribbing</surname><given-names>J</given-names></name><name><surname>Jonsson</surname><given-names>EN</given-names></name></person-group><article-title>Power, selection bias and predictive performance of the population pharmacokinetic covariate model</article-title><source>J Pharmacokinet Pharmacodyn.</source><year>2004</year><volume>31</volume><fpage>109</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1023/B:JOPA.0000034404.86036.72</pub-id><pub-id pub-id-type="pmid">15379381</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norris</surname><given-names>V</given-names></name><name><surname>Zhu</surname><given-names>C</given-names></name><name><surname>Ambery</surname><given-names>C</given-names></name></person-group><article-title>The pharmacodynamics of GSK961081 in patients with COPD</article-title><source>Eur Respir J.</source><year>2011</year><volume>38</volume><issue>Suppl. 55</issue><fpage>823</fpage></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calzetta</surname><given-names>L</given-names></name><name><surname>Cazzola</surname><given-names>M</given-names></name><name><surname>Page</surname><given-names>CP</given-names></name><name><surname>Rogliani</surname><given-names>P</given-names></name><name><surname>Facciolo</surname><given-names>F</given-names></name><name><surname>Matera</surname><given-names>MG</given-names></name></person-group><article-title>Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways</article-title><source>Pulm Pharmacol Ther.</source><year>2015</year><volume>32</volume><fpage>15</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.pupt.2015.03.007</pub-id><pub-id pub-id-type="pmid">25899618</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cazzola</surname><given-names>M</given-names></name><name><surname>Calzetta</surname><given-names>L</given-names></name><name><surname>Page</surname><given-names>C</given-names></name><name><surname>Rogliani</surname><given-names>P</given-names></name><name><surname>Facciolo</surname><given-names>F</given-names></name><name><surname>Gavald&#x000e0;</surname><given-names>A</given-names></name><name><surname>Matera</surname><given-names>MG</given-names></name></person-group><article-title>Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi</article-title><source>Eur J Pharmacol.</source><year>2014</year><volume>745</volume><fpage>135</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2014.10.025</pub-id><pub-id pub-id-type="pmid">25446566</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cazzola</surname><given-names>M</given-names></name><name><surname>Calzetta</surname><given-names>L</given-names></name><name><surname>Segreti</surname><given-names>A</given-names></name><name><surname>Facciolo</surname><given-names>F</given-names></name><name><surname>Rogliani</surname><given-names>P</given-names></name><name><surname>Matera</surname><given-names>MG</given-names></name></person-group><article-title>Translational study searching for synergy between glycopyrronium and indacaterol</article-title><source>COPD.</source><year>2015</year><volume>12</volume><fpage>175</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.3109/15412555.2014.922172</pub-id><pub-id pub-id-type="pmid">25222881</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calzetta</surname><given-names>L</given-names></name><name><surname>Page</surname><given-names>P</given-names></name><name><surname>Spina</surname><given-names>D</given-names></name><name><surname>Cazzola</surname><given-names>M</given-names></name><name><surname>Rogliani</surname><given-names>P</given-names></name><name><surname>Facciolo</surname><given-names>F</given-names></name><name><surname>Matera</surname><given-names>MG</given-names></name></person-group><article-title>Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone</article-title><source>J Pharmacol Exp Ther.</source><year>2013</year><volume>346</volume><fpage>414</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1124/jpet.113.204644</pub-id><pub-id pub-id-type="pmid">23766543</pub-id></element-citation></ref></ref-list></back></article>